Skip to content
← Catalog

Mol Cancer 2026 · CAR-NK cell therapy review · Liu/Cao

"Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable efficacy in hematologic malignancies; however, its clinical application is limited by toxicities, such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and graft-ve…

Type
paper
Domain
oncology
Grade
conference
License
LIGHT_HOPE_proprietary
Provenance
m622_verify_wave_3_2026-05-16
evidence_grade
A
category
car_nk_review
status
verified
instance_tag
sunvax-antibody-2025
clinical_claim_softening
"review · preclinical/early-clinical CAR-NK landscape · not intended to guide individual patient treatment choices"
journal
Molecular Cancer
year
2026
authors
Weitong Liu,Xinxin Cao
abstract_snippet
"Chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable efficacy in hematologic malignancies; however, its clinical application is limited by toxicities, such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and graft
pmid
41882710
doi
10.1186/s12943-026-02648-z
View at source ↗

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.